Status
Conditions
Treatments
About
This data collection is designed to provide evidence for the safety, performance, and clinical benefit of BIOTRONIK's EP products. Additionally, residual risks will be monitored and newly emerging risks identified.
Full description
In this study, data from routine care will be collected and evaluated to support regulatory post-market clinical follow-up demands under MDR as well as maintenance of the regulatory approval of the BIOTRONIK's EP product portfolio in the CE region. This is a prospective, observational, multi-center, international, open-label, non-randomized study that aims to provide evidence for the clinical safety, performance, and clinical benefit of BIOTRONIK's EP products. The patients participating in the study either receive a diagnostic or therapeutic catheter intervention, which are indicated for temporary transvenous application in patients with cardiac arrhythmias. They will be used in combination with external devices like RF generators, external pacemakers cardiac stimulators and / or irrigation pumps.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Indication for diagnostic or therapeutic EP intervention
EP intervention is planned to involve the use of BIOTRONIK EP products from at least 2 of the 3 following categories:
BIOTRONIK EP product is planned to be used within its intended purpose
Ability to understand the nature of the study
Willingness to provide written informed consent
Ability and willingness to perform all follow-up visits at the study site
Exclusion criteria
Loading...
Central trial contact
Ines Danzke; Annette Thiem, Dr.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal